{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:50:59Z","timestamp":1769604659974,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0234-1","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T04:05:06Z","timestamp":1530677106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats"],"prefix":"10.1186","volume":"19","author":[{"given":"Yichen","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisheng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiming","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"issue":"4","key":"234_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/j.1552-4604.1996.tb04207.x","volume":"36","author":"R Bullingham","year":"1996","unstructured":"Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36(4):315\u201324.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"234_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00228-014-1771-1","volume":"71","author":"J Ling","year":"2015","unstructured":"Ling J, Shi J, Jiang Q, et al. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur J Clin Pharmacol. 2015;71(1):95\u2013106.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"234_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1023\/A:1015828802490","volume":"7","author":"WA Lee","year":"1990","unstructured":"Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res. 1990;7(2):161\u20136.","journal-title":"Pharm Res"},{"issue":"21","key":"234_CR4","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.2146\/ajhp040380","volume":"62","author":"GR Ingle","year":"2005","unstructured":"Ingle GR, Shah T. Enteric-coated mycophenolate sodium for transplant immunosuppression. Am J Health Syst Pharm. 2005;62(21):2252\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"234_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.trre.2012.02.001","volume":"26","author":"M Cooper","year":"2012","unstructured":"Cooper M, Salvadori M, Budde K, et al. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando). 2012;26(4):233\u201340.","journal-title":"Transplant Rev (Orlando)"},{"issue":"5","key":"234_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/00007890-199609150-00022","volume":"62","author":"LJ Langman","year":"1996","unstructured":"Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62(5):666\u201372.","journal-title":"Transplantation"},{"issue":"2","key":"234_CR7","first-page":"925","volume":"28","author":"RE Bullingham","year":"1996","unstructured":"Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28(2):925\u20139.","journal-title":"Transplant Proc"},{"issue":"6","key":"234_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","volume":"64","author":"MD Hale","year":"1998","unstructured":"Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64(6):672\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"234_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","volume":"68","author":"T van Gelder","year":"1999","unstructured":"van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68(2):261\u20136.","journal-title":"Transplantation"},{"issue":"5","key":"234_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.bjp.0702399","volume":"126","author":"M Shipkova","year":"1999","unstructured":"Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999;126(5):1075\u201382.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"234_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","volume":"24","author":"M Behrend","year":"2001","unstructured":"Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24(9):645\u201363.","journal-title":"Drug Saf"},{"issue":"7","key":"234_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/ctr.12379","volume":"28","author":"R Lopez-Solis","year":"2014","unstructured":"Lopez-Solis R, DeVera M, Steel J, et al. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transpl. 2014;28(7):783\u20138.","journal-title":"Clin Transpl"},{"key":"234_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/CEG.S81922","volume":"8","author":"B Manger","year":"2015","unstructured":"Manger B, Hiepe F, Schneider M, et al. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol. 2015;8:205\u201313.","journal-title":"Clin Exp Gastroenterol"},{"key":"234_CR14","unstructured":"Behrend M, Grinyo J, Vanrenterghem Y, et al. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation, 1999;68(3):391-6."},{"issue":"2","key":"234_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","volume":"4","author":"K Budde","year":"2004","unstructured":"Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4(2):237\u201343.","journal-title":"Am J Transplant"},{"issue":"5","key":"234_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/j.1600-6143.2005.00778.x","volume":"5","author":"HU Meier-Kriesche","year":"2005","unstructured":"Meier-Kriesche HU, Davies NM, Grinyo J, et al. Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant. 2005;5(5):1164. author reply 1165-1166","journal-title":"Am J Transplant"},{"issue":"8","key":"234_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00007890-199810270-00027","volume":"66","author":"D Ducloux","year":"1998","unstructured":"Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66(8):1115\u20136.","journal-title":"Transplantation"},{"issue":"5","key":"234_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.TP.0000053753.43268.F0","volume":"75","author":"BD Maes","year":"2003","unstructured":"Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75(5):665\u201372.","journal-title":"Transplantation"},{"issue":"2","key":"234_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","volume":"4","author":"M Salvadori","year":"2004","unstructured":"Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4(2):231\u20136.","journal-title":"Am J Transplant"},{"issue":"1","key":"234_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00007890-199101000-00003","volume":"51","author":"KP Platz","year":"1991","unstructured":"Platz KP, Sollinger HW, Hullett DA, et al. RS-61443--a new, potent immunosuppressive agent. Transplantation. 1991;51(1):27\u201331.","journal-title":"Transplantation"},{"issue":"9","key":"234_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","volume":"14","author":"GA Knoll","year":"2003","unstructured":"Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003;14(9):2381\u20136.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"234_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","volume":"17","author":"RP Pelletier","year":"2003","unstructured":"Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transpl. 2003;17(3):200\u20135.","journal-title":"Clin Transpl"},{"issue":"10","key":"234_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1432-2277.2004.tb00394.x","volume":"17","author":"KL Hardinger","year":"2004","unstructured":"Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int. 2004;17(10):609\u201316.","journal-title":"Transpl Int"},{"issue":"2","key":"234_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1399-0012.2004.00318.x","volume":"19","author":"W Arns","year":"2005","unstructured":"Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transpl. 2005;19(2):199\u2013206.","journal-title":"Clin Transpl"},{"issue":"5","key":"234_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1399-0012.2008.00820.x","volume":"22","author":"KL Hardinger","year":"2008","unstructured":"Hardinger KL, Hebbar S, Bloomer T, et al. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant. 2008;22(5):555\u201361.","journal-title":"Clin Transplant"},{"issue":"3","key":"234_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"HW Sollinger","year":"1995","unstructured":"Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. renal transplant mycophenolate Mofetil study group. Transplantation. 1995;60(3):225\u201332.","journal-title":"Transplantation"},{"key":"234_CR27","doi-asserted-by":"crossref","unstructured":"The U.S. Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. Transplant Proc. 1997;29(1-2): 348-9.","DOI":"10.1016\/S0041-1345(96)00302-8"},{"issue":"1","key":"234_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1358\/mf.1999.21.1.527017","volume":"21","author":"R Atanassova","year":"1999","unstructured":"Atanassova R, Petkov O, Ivanov C, et al. Effects of 4-(4-bromophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride on acute gastric lesions, acid secretion in rats and on some hemodynamic parameters in cats. Methods Find Exp Clin Pharmacol. 1999;21(1):39\u201346.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"234_CR29","first-page":"274","volume":"27","author":"H Bellamlih","year":"2017","unstructured":"Bellamlih H, Bouimetarhan L, Amil T, et al. Rare digestive tumors: gastrointestinal stromal tumors (GISTs): about a case of small bowel location and literature review. Pan Afr Med J. 2017;27:274.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"234_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12272-011-0107-2","volume":"34","author":"JW Gao","year":"2011","unstructured":"Gao JW, Peng ZH, Li XY, et al. Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. Arch Pharm Res. 2011;34(1):59\u201369.","journal-title":"Arch Pharm Res"},{"issue":"12","key":"234_CR31","first-page":"6667","volume":"37","author":"CA Rubio","year":"2017","unstructured":"Rubio CA. Updated histologic classification of adenomas and carcinomas in the Colon of carcinogen-treated Sprague-Dawley rats. Anticancer Res. 2017;37(12):6667\u201370.","journal-title":"Anticancer Res"},{"issue":"3","key":"234_CR32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0016-5085(82)80198-4","volume":"83","author":"ER Lacy","year":"1982","unstructured":"Lacy ER, Ito S. Microscopic analysis of ethanol damage to rat gastric mucosa after treatment with a prostaglandin. Gastroenterology. 1982;83(3):619\u201325.","journal-title":"Gastroenterology"},{"issue":"12","key":"234_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2165\/0003088-200847120-00007","volume":"47","author":"BC de Winter","year":"2008","unstructured":"de Winter BC, van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet. 2008;47(12):827\u201338.","journal-title":"Clin Pharmacokinet"},{"key":"234_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.12659\/AOT.889691","volume":"19","author":"J Belliere","year":"2014","unstructured":"Belliere J, Esposito L, Gandia P, et al. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. Ann Transplant. 2014;19:76\u201381.","journal-title":"Ann Transplant"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0234-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0234-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0234-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T02:02:25Z","timestamp":1604541745000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0234-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["234"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0234-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"7 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocol was approved by the Committee of Animal Care of Fudan University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}